Sotera Health (SHC)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$18.90-0.68%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · SHC
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-09-06. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $19 SHC trades at 20× p/e, below its 23× p/e peer median, but our blended $15 fair value sits below the price. It's a high-confidence read. Even valued only for durable growth at sustainable margins, it's worth about $21 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| dcf fcfe | 12M | $3.04 | — | — | Analyst | high |
| dcf fcff | 12M | $16.61 | — | — | Analyst | high |
| graham number | 12M | $6.99 | — | — | TTM | high |
| Peer P/FCF | 12M | $8.44 | 21.6 | 0.39 | TTM | high |
| Peer P/E | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price the business can't be justified by any reasonable horizon of the forecast growth; the price already runs past what the model can underwrite. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $0.04/sh owner earnings.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $19.24 |
| 18.4 |
| 1.05 |
| ntm analyst |
| high |
| Peer P/S | 12M | $15.87 | 3.8 | 4.22 | TTM | high |
| PEG | 12M | $20.97 | 22.3 | 0.94 | TTM | high |
| residual income | 12M | $5.23 | — | — | TTM | high |
| Own P/E history | 12M | $18.34 | 19.5 | 0.94 | TTM | high |
| triangulated | 12M | $22.76 | 22.9 | 0.99 | Triangulated | high |
| Peer P/E | 3Y | $22.06 | 18.4 | 1.20 | Analyst | medium |
| Peer P/S | 3Y | $19.24 | 3.8 | 5.12 | Analyst | medium |
| PEG | 3Y | $26.76 | 22.3 | 1.20 | Analyst | medium |
| Own P/E history | 3Y | $23.40 | 19.5 | 1.20 | Analyst | medium |
| Peer P/E | 5Y | $25.01 | 18.4 | 1.36 | Analyst | high |
| Peer P/S | 5Y | $21.81 | 3.8 | 5.80 | Analyst | high |
| PEG | 5Y | $30.33 | 22.3 | 1.36 | Analyst | high |
| Own P/E history | 5Y | $26.53 | 19.5 | 1.36 | Analyst | high |